These studies contributed to the design of two clinical trials; one examining radiation, cyclophosphamide, and anti-OX40 in patients with metastatic prostate cancer (NCT01303705); and the other using combination stereotactic body radiation and anti-OX40 in patients with metastatic breast cancer (NCT01862900). The gene discussed is TNFRSF4; the disease is metastatic prostate carcinoma.